Session » (2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 2177

Characterization of Crevicular Fluid Microbiota in Primary Sjögren’s Syndrome

Abstract Number: 2178

Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study

Abstract Number: 2179

Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey

Abstract Number: 2180

Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome

Abstract Number: 2181

Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients

Abstract Number: 2182

Mitochondrial Alterations in Primary Sjögren´s Syndrome

Abstract Number: 2183

Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients

Abstract Number: 2184

Development of Salivary Gland Organoids to Study Sjögren Syndrome

Abstract Number: 2185

35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study

Abstract Number: 2186

Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life

Abstract Number: 2187

Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome

Abstract Number: 2188

Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis

Abstract Number: 2189

Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement

Abstract Number: 2190

Saliclick: A Novel Technology for Minimal Invasive Salivary Gland Biopsy in Suspected Sjögren’s Syndrome

Abstract Number: 2191

Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease

Abstract Number: 2192

New Inducible Mouse Model of Sjögren’s Syndrome Represents a Valuable Tool to Assess the Impact of Gene Knockout on the Disease’s Physiopathology

Abstract Number: 2193

Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement

Abstract Number: 2194

Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.